Compare MBUU & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | RXST |
|---|---|---|
| Founded | 1982 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 524.6M |
| IPO Year | 2014 | 2021 |
| Metric | MBUU | RXST |
|---|---|---|
| Price | $33.80 | $9.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 11 |
| Target Price | ★ $33.88 | $11.40 |
| AVG Volume (30 Days) | 168.9K | ★ 932.3K |
| Earning Date | 01-30-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $830,714,000.00 | $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.92 | $4.12 |
| P/E Ratio | $34.24 | ★ N/A |
| Revenue Growth | ★ 11.54 | 10.75 |
| 52 Week Low | $24.07 | $6.32 |
| 52 Week High | $42.49 | $34.71 |
| Indicator | MBUU | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 42.69 |
| Support Level | $31.77 | $9.47 |
| Resistance Level | $34.44 | $10.16 |
| Average True Range (ATR) | 1.22 | 0.61 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 86.15 | 48.59 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.